ArticleNorth American journal of medicine & science2016
Chronic Hepatitis C Virus Infection: A Review of Current Direct-Acting Antiviral Treatment Strategies.
Article in North American journal of medicine & science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03341988 (Evaluation of the Clinical Effects of Ombitasvir/Paritaprevir/Ritonavir Regimen in the Treatment of Chronic HCV Patients in CKD Versus ESRD Patients in Assiut University Hospital), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Clinical Effects of Ombitasvir/Paritaprevir/Ritonavir Regimen in the Treatment of Chronic HCV Patients in CKD Versus ESRD Patients in Assiut University Hospital
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- The Inhibitory Potential of 2'-dihalo Ribonucleotides against HCV: Molecular Docking, Molecular Simulations, MM-BPSA, and DFT Studies.Molecules (Basel, Switzerland) · 2022Article
- Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.Archives of virology · 2020Article
- Post-infantile giant cell hepatitis: A single center's experience over 25 years.World journal of hepatology · 2019Article
- Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization.Journal of clinical and translational hepatology · 2018Article
- A Descriptive Analysis of a Community Clinic Providing Hepatitis C Treatment to Poor and Uninsured Patients.Journal of community health · 2018Article
- Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.World journal of gastroenterology · 2018Review
- Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.International journal of clinical pharmacy · 2018Observational
- Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?IDCases · 2018Article
- The Complement System and C1q in Chronic Hepatitis C Virus Infection and Mixed Cryoglobulinemia.Frontiers in immunology · 2018Review
- Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.Journal of cellular and molecular medicine · 2017Review
- Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions.Journal of virology · 2017Article
- Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor.ACS medicinal chemistry letters · 2017Article
- Review
- Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience.Arthritis research & therapy · 2017Article
- Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.Antiviral research · 2017Article
- Hepatitis C treatment: where are we now?International journal of general medicine · 2017Review
- Review
- Intergenotypic 2k/1b hepatitis C virus recombinants in the East Macedonia and Thrace region of Greece.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Chronic Hepatitis C virus (HCV) infection carries a significant clinical burden in the United States, affecting more than 4.6 million Americans. Untreated chronic HCV infection can result in cirrhosis, portal hypertension, and hepatocellular carcinoma. Previous interferon based treatment carried low rates of success and significant adverse effects. The advent of new generation oral antiviral therapy has led to major improvements in efficacy and tolerability but has also resulted in an explosion of data with increased treatment choice complexity. Treatment guidelines are constantly evolving due to emerging regimens and real world treatment data. There also still remain subpopulations for whom current treatments are lacking or unclearly defined. Thus, the race for development of HCV treatment regimens still continues. This review of the current literature will discuss the current recommended treatment strategies and briefly overview next generation agents.
Indexed as
Identifiers
27293521PMC4897966W2471029913What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.